Eli Lilly and Company (LILY34) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eli Lilly and Company (LILY34) has a cash flow conversion efficiency ratio of 0.171x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$5.33 Billion ≈ $1.05 Billion USD) by net assets (R$31.20 Billion ≈ $6.12 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Eli Lilly and Company for the company's overall valuation and market capitalisation.
Eli Lilly and Company - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Eli Lilly and Company's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eli Lilly and Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eli Lilly and Company ranked by their cash flow conversion efficiency. Explore Eli Lilly and Company cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Walmart Inc. Common Stock
NYSE:WMT
|
0.095x |
|
JPMorgan Chase & Co
NYSE:JPM
|
-0.067x |
|
Samsung Electronics Co Ltd
KO:005930
|
0.055x |
|
Eli Lilly and Company
NYSE:LLY
|
0.316x |
|
Walmart Inc.
NASDAQ:WMT
|
0.143x |
|
Micron Technology Inc
NASDAQ:MU
|
0.164x |
|
Advanced Micro Devices Inc
NASDAQ:AMD
|
0.035x |
|
SK Hynix Inc
KO:000660
|
0.143x |
Annual Cash Flow Conversion Efficiency for Eli Lilly and Company (2014–2025)
The table below shows the annual cash flow conversion efficiency of Eli Lilly and Company from 2014 to 2025. View latest Eli Lilly and Company stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$26.54 Billion ≈ $5.21 Billion |
R$16.81 Billion ≈ $3.30 Billion |
0.634x | +2.55% |
| 2024-12-31 | R$14.27 Billion ≈ $2.80 Billion |
R$8.82 Billion ≈ $1.73 Billion |
0.618x | +17.48% |
| 2023-12-31 | R$10.86 Billion ≈ $2.13 Billion |
R$5.71 Billion ≈ $1.12 Billion |
0.526x | -20.94% |
| 2022-12-31 | R$10.65 Billion ≈ $2.09 Billion |
R$7.08 Billion ≈ $1.39 Billion |
0.665x | -16.13% |
| 2021-12-31 | R$9.15 Billion ≈ $1.80 Billion |
R$7.26 Billion ≈ $1.42 Billion |
0.793x | -31.16% |
| 2020-12-31 | R$5.64 Billion ≈ $1.11 Billion |
R$6.50 Billion ≈ $1.28 Billion |
1.152x | -37.90% |
| 2019-12-31 | R$2.61 Billion ≈ $511.52 Million |
R$4.84 Billion ≈ $949.03 Million |
1.855x | +230.08% |
| 2018-12-31 | R$9.83 Billion ≈ $1.93 Billion |
R$5.52 Billion ≈ $1.08 Billion |
0.562x | +16.03% |
| 2017-12-31 | R$11.59 Billion ≈ $2.27 Billion |
R$5.62 Billion ≈ $1.10 Billion |
0.484x | +39.88% |
| 2016-12-31 | R$14.01 Billion ≈ $2.75 Billion |
R$4.85 Billion ≈ $951.85 Million |
0.346x | +70.44% |
| 2015-12-31 | R$14.59 Billion ≈ $2.86 Billion |
R$2.96 Billion ≈ $581.71 Million |
0.203x | -29.87% |
| 2014-12-31 | R$15.39 Billion ≈ $3.02 Billion |
R$4.46 Billion ≈ $874.82 Million |
0.290x | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more